TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01666496

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental Video Game
Description: Participants will play either the experimental or the control videogame for 6 weeks. Both interventions will be provided during 12 sessions, twice weekly for 6 weeks; each session will involve one and one-quarter hour of game play.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Off the Shelf Video Game
Description: Participants will play either the experimental or the control videogame for 6 weeks. Both interventions will be provided during 12 sessions, twice weekly for 6 weeks; each session will involve one and one-quarter hour of game play.
Study: NCT02097004

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: once weekly 180 μg subcutaneous injection for 48 weeks

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alfa-2a
Description: once weekly 180 μg subcutaneous injection for 48 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: once weekly 180 μg subcutaneous injection for 48 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBV vaccination
Description: 1.0 mL (20 μg) intramuscular injection at 4, 8, 12 and 28 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBV vaccination
Description: 1.0 mL (20 μg) intramuscular injection at 4, 8, 12 and 28 weeks
Study: NCT03432117

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fixed respiratory rehabilitation
Description: There are 6 step-exercise presented in the application and initial target of exercise will be set according to subject condition. After subject completes targeted exercise, next step will be started.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Responsive respiratory rehabilitation
Description: The application provide responsive exercise program by changing type and numbers of exercise according to subject condition and exercise ability (This will be assessed with monitored O2 saturation, symptom of dyspnea and pulse rate during exercise)
Study: NCT02208986

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triptorelin
Description: Triptorelin is given by s.c injection for ovulation triggering.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triptorelin
Description: Triptorelin is given by s.c injection for ovulation triggering.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triptorelin
Description: Triptorelin is given by s.c injection for ovulation triggering.
Study: NCT00190190

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: With Peeling of Limiting the Intern of the Retina
Description: With Peeling of Limiting the Intern of the Retina

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Internal limiting membrane peeling
Description: Traditional Procedure Without Peeling of Limiting
Study: NCT02323516

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic acid + loperamide
Description: In case of inefficiency in one month, according to predefined criteria, acetylsalicylic acid will be stopped and replaced by diosmectite.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diosmectite + loperamide
Description: In case of inefficiency in one month, according to predefined criteria, diosmectite will be stopped and replaced by acetylsalicylic acid.
Study: NCT01913925

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tyrosine-Containing Food Bar
Study: NCT03431506

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Vestibular rehabilitation
Description: Vestibular Rehabilitation Exercises

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation
Description: Vestibular Rehabilitation Exercises
Study: NCT01944488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH agonist
Description: 100 µg/m2 body surface max 100 µg i.v.
Study: NCT01500941

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: probiotics
Description: a mixture of Lactobacillus LS01 DSM 2275 and Bifidobacterium BR03 DSM 16604 at a dose of 1 x 109 colony forming units (CFU)/g each in maltodextrin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: maltodextrin
Description: sachets
Study: NCT03518489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lappaconitine Adhesive Patch
Description: to evaluate the efficacy of lappaconitine adhesive patch in alleviation radiation induced mucositis pain

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard care
Description: Standard care will include mouth wash with antibiotics.
Study: NCT02480062

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mWELLCARE
Description: mWELLCARE intervention arm will include a software application loaded on a tablet computer that will be used by Nurse Care Coordinators (posted in community health centers) in the course of their jobs to register patients with hypertension or diabetes, to generate clinical decision support recommendations, to track these patients over time and to improve follow-up care. Decision support recommendations will be printed and given to a doctor, who will make the final call on the management plan that will be used for the patient. Registered patients will also receive customized messages on their mobile phone. In addition, at sites where network connectivity permits, the doctor may also be equipped with a doctor's app on a tablet that will be largely the same as the NCC app.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care at the community health centers
Study: NCT00493155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG1530
Description: Administered po at escalating doses (10 cohorts)
Study: NCT05097157

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Potenza
Description: Subjects are treated with the Potenza™ device if they present with conditions such as, but not limited to: wrinkles, fine lines, crepey skin, acne scars, active acne, enlarged pores, stretch marks, or loose skin on the face, neck and/or body.
Study: NCT03809247

Intervention type: OTHER
Description: have no any intervention

Intervention type: OTHER
Description: have no any intervention
Study: NCT00770224

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tositumomab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Study: NCT02097004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Continue Entecavir(0.5mg) for 100 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir
Description: Continue Entecavir(0.5mg) for 100 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Continue Entecavir(0.5mg) for 100 weeks
Study: NCT00770224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: tositumomab
Study: NCT04186663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silver Diamine Fluoride
Description: 38% aqueous silver diamine fluoride \[Ag(NH3)\]2F, CAS RN 33040-28-7
Study: NCT04545034

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: water aerobic exercise
Description: The EP would be formed by continuous session of dynamic water aerobic exercise which consisted of a dynamic warm-up period (5 minutes), an active exercise period at the established intensity of HR (35 minutes), and a cooldown period (5 minutes) to total 45 minutes, with a intensity of 75%HR.
Study: NCT01784614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2624803 - Solution
Description: Administered orally as reconstituted solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2624803 - Capsule
Description: Administered orally as a capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2624803 - Capsule
Description: Administered orally as a capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2624803 - Capsule
Description: Administered orally as a capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo - Solution
Description: Administered orally as solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo - Solution
Description: Administered orally as solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo - Solution
Description: Administered orally as solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Solution
Description: Administered orally as solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo - Capsule
Description: Administered orally as a capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Capsule
Description: Administered orally as a capsule
Study: NCT01484561

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CP-690,550 or Placebo
Description: CP-690,550 10 mg twice a day (BID) orally or placebo BID orally, approximately 72 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo BID orally, approximately 72 days
Study: NCT02456454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: Liquid risperidone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid
Description: Liquid valproic acid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04058158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB12 (proposed eculizumab biosimilar)
Description: 600 mg IV every week for first 4 weeks and 900 mg for the fifth week, followed by 900 mg every 2 weeks thereafter

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB12 (proposed eculizumab biosimilar)
Description: 600 mg IV every week for first 4 weeks and 900 mg for the fifth week, followed by 900 mg every 2 weeks thereafter

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soliris (eculizumab)
Description: 600 mg IV every week for first 4 weeks and 900 mg for the fifth week, followed by 900 mg every 2 weeks thereafter

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soliris (eculizumab)
Description: 600 mg IV every week for first 4 weeks and 900 mg for the fifth week, followed by 900 mg every 2 weeks thereafter
Study: NCT02036268

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard
Description: Standard ostomy education

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard
Description: Standard ostomy education

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard
Description: Standard ostomy education

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre-operative Education
Description: In addition to standard ostomy education, an additional pre-operative ostomy education session will be conducted with the subject.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre-operative Education
Description: In addition to standard ostomy education, an additional pre-operative ostomy education session will be conducted with the subject.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Two-week Post Operative Education
Description: In addition to standard ostomy education and an additional pre-operative ostomy education session, another ostomy education session will be conducted with the subject two weeks post-op.
Study: NCT05204758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCM Formula
Description: three packages of TCM preparations with each meal three times a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: three packages of placebo preparations with each meal three times a day
Study: NCT04125875

Intervention type: DIAGNOSTIC_TEST
Intervention: Electrogastrogram(EGG)
Description: Heart Rate Variability

Intervention type: DIAGNOSTIC_TEST
Intervention: Electrogastrogram(EGG)
Description: Heart Rate Variability

Intervention type: DIAGNOSTIC_TEST
Intervention: Heart Rate Variability(HRV)
Description: Heart Rate Variability

Intervention type: DIAGNOSTIC_TEST
Intervention: Heart Rate Variability(HRV)
Description: Heart Rate Variability
Study: NCT00291187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 mg VEC-162
Description: 20 mg VEC-162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 mg VEC-162
Description: 50 mg VEC-162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg VEC-162
Description: 100 mg VEC-162

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02361489

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: V-Go
Description: Initiation and titration of V-Go® using one of two dose titration algorithms to achieve improved A1C at 4 months.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: V-Go
Description: Initiation and titration of V-Go® using one of two dose titration algorithms to achieve improved A1C at 4 months.
Study: NCT01068613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAX028
Description: QAX028 60 mcg via inhalation device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAX028
Description: QAX028 20 mcg via inhalation device

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: Tiotropium via inhalation device

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to QAX028 via inhalation device
Study: NCT03356808

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lung cancer-specific T cells
Description: 1 infusion, for 1x10\^6\~1x10\^7 cells/kg via IV
Study: NCT04663542

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: immobilization duration
Description: brace immobilization duration after open surgery for Achilles tendon rupture

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: immobilization duration
Description: brace immobilization duration after open surgery for Achilles tendon rupture

Intervention type: PROCEDURE
Group type: OTHER
Intervention: immobilization duration
Description: brace immobilization duration after open surgery for Achilles tendon rupture

Intervention type: PROCEDURE
Group type: OTHER
Intervention: immobilization duration
Description: brace immobilization duration after open surgery for Achilles tendon rupture
Study: NCT01852916

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: Nasal Continuous Positive Airway Pressure Ventilation using Infant Flow CPAP machine

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NHFOV
Description: Nasal High Frequency Oscillatory Ventilation
Study: NCT04324775

Intervention type: OTHER
Intervention: Exercise + Manual Lymphatic Drainage
Description: Quadriceps exercises with weight of 75%1 Max repetition and 8 repetionX3 sets Following exercises, manual lymphatic drainage applied to rectus femoris for 5 minutes

Intervention type: OTHER
Intervention: Exercise + Swedish massage
Description: Quadriceps exercises with weight of 75%1 Max repetition and 8 repetionX3 sets Following exercises, swedish massage applied to rectus femoris for 5 minutes
Study: NCT02260388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nortriptyline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mexiletine
Study: NCT04077762

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radial Access
Description: Radial Access

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: State-of-the-art femoral access with 18 gauge needle
Description: State-of-the-art femoral access with 18 gauge needle

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: State-of-the-art femoral access with 21 gauge needle
Description: State-of-the-art femoral access with 21 gauge needle. For patients randomized to micropuncture (21G) the micropuncture wire must be advanced under fluoroscopy to avoid inadvertent wiring of side-branches.
Study: NCT04458545

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oxy(Gly)4-sKLH vaccine - Low Dose
Description: Oxy(Gly)4-sKLH vaccine - Low Dose
Study: NCT01913925

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Bar
Study: NCT01470911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB010
Description: Six ascending dose groups (DG) are planned, with a total of 48 subjects. DG 1 and 2 will consist of n=6 subjects (n=3 receiving SB010, n=3 placebo). The following DG will consist of n=9 subjects (n=6 receiving SB010, n=3 placebo). The number of subjects to be exposed to active compound will be limited on a particular study day. Subjects of a particular DG will be divided into subgroups and exposed to the drug on different days. In DG 1 and 2, the time interval between the two administrations of the first subgroup will be at least 2 hours. In DG 3-6, the time interval between two subsequent administrations will be at least 1 hour.~Dose level (DL) 1: 0.4 mg hgd40/2 mL; DL 2: 2 mg hgd40/2 mL; DL 3: 5 mg hgd40/2 mL; DL 4: 10 mg hgd40/2 mL; DL 5: 20 mg hgd40/2 mL; DL 6: 40 mg hgd40/2 mL.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Six ascending dose groups (DG) are planned, with a total of 48 subjects. DG 1 and 2 will consist of n=6 subjects (n=3 receiving SB010, n=3 placebo). The following DG will consist of n=9 subjects (n=6 receiving SB010, n=3 placebo). The number of subjects to be exposed to active compound will be limited on a particular study day. Subjects of a particular DG will be divided into subgroups and exposed to the drug on different days. In DG 1 and 2, the time interval between the two administrations of the first subgroup will be at least 2 hours. In DG 3-6, the time interval between two subsequent administrations will be at least 1 hour.
Study: NCT04568473

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PRG Barrier Coat (By SHOFU Inc., Japan)
Description: PRG Barrier Coat (By SHOFU Inc., Japan) is a bioactive, resin-based varnish based on the proprietary Giomer concept which incorporates the patented bioactive S-PRG (Surface Pre-Reacted Glass ionomer) filler technology, where a unique combination of six beneficial ions are actively gradually released to provide a smart solution to revolutionize dentin hypersensitivity protocol
Study: NCT02887638

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individual Profile Analysis (Physical therapy Intervention)
Description: The Individual Profile Analysis consists of the following components:~* Analysis of the sitting-posture profile:~  o cervical spine, thoracic spine, lumbar spine and pelvis during a longitudinal provoking task (working at a laptop).~* Analysis of the dural profile before and after the provoking task:~  o Determination of the dural sensitivity by the use of the slump-test~* Analysis of the pain profile before and after the provoking task:~  * Determination of pressure pain sensitivity by the use of pressure algometry~ * Determination of the influence of pain on the quality of life by the use of the HIT-6 questionnaire
Study: NCT04458545

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oxy(Gly)4-sKLH vaccine - High Dose
Description: Oxy(Gly)4-sKLH vaccine - high dose

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oxy(Gly)4-sKLH vaccine
Description: Oxy(Gly)4-sKLH vaccine - Placebo
Study: NCT04735809

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whole Cell Algae Fermentate
Description: Contains at minimum 50% Beta Glucan

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: microcrystalline cellulose
Study: NCT01153672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Optional correlative studies
Study: NCT01916720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-480848 40 mg
Description: Study Drug
Study: NCT02764138

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Building a Strong Identity and Coping Skills
Description: Psychoeducational program to teach children coping skills, healthy identity development, and collective social action.
Study: NCT03744936

Intervention type: OTHER
Intervention: Feedback
Description: Study team members will conduct interviews with subjects to gather feedback on Atrial Fibrillation experiences
Study: NCT06790303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Feladilimab
Description: Feladilimab will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab will be administered
Study: NCT03055013

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nephrectomy
Description: Undergo nephrectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nephrectomy
Description: Undergo nephrectomy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Observation
Description: Undergo observation
Study: NCT01916720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-480848 80 mg
Description: Study Drug
Study: NCT03055013

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02107703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered Orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Administered IM

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fulvestrant
Description: Administered IM

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered Orally
Study: NCT04868227

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: FULTIUM D3 VITAMIN D3
Description: VITAMIN D3 SUPPLEMENT
Study: NCT00001160

Intervention type: DRUG
Intervention: 68-Gallium Dotatate
Description: For evaluation risk/benefit evaluation

Intervention type: DRUG
Intervention: 68-Gallium Dotatate
Description: For evaluation risk/benefit evaluation
Study: NCT01153672

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: F-18 16 alpha-fluoroestradiol
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Correlative studies